Evidence library → Evidence answer

What is BIA-ALCL and how rare is it?

C Limited evidenceEvidence answer
Educational summary of published research, generated by our evidence engine and pending editorial review. Not medical advice, and not a substitute for consultation with a qualified clinician who has examined you. Full disclaimer

⚠️ Contact your surgeon if you notice these symptoms

If you have breast implants and experience sudden swelling, breast enlargement, asymmetry, pain, or a new lump, especially years after your surgery, please contact your surgeon promptly. These can be signs of a seroma (fluid collection) that needs evaluation for BIA-ALCL. Do not wait to be seen.

Short answer

BIA-ALCL stands for breast implant-associated anaplastic large cell lymphoma, a rare type of immune-system cancer (lymphoma) linked almost exclusively to textured breast implants. It is uncommon, but its exact frequency is still not fully known. When caught early, the outlook is usually very good.

What is BIA-ALCL?

BIA-ALCL is a type of non-Hodgkin lymphoma, meaning it is a cancer that starts in certain immune cells called T-cells. [6] It is not a breast cancer in the traditional sense. Instead, it develops in the fluid or tissue surrounding a breast implant. [5] The World Health Organization officially recognized it as a distinct disease entity in 2016 and updated that classification in 2017. [4][5]

It is closely linked to textured-surface breast implants. Smooth implants have not been meaningfully associated with the condition. [6] The exact reason textured implants appear to trigger BIA-ALCL is still being studied, but theories include chronic low-grade bacterial infection (biofilm), the immune system's reaction to the rough surface, and possible genetic susceptibility in certain individuals. [4][7]

How rare is it, and when does it appear?

BIA-ALCL is considered uncommon, and researchers are frank that the exact incidence and prevalence are not yet fully known. [4] What is known is that cases have been increasing as awareness has grown, which has made it a recognized public health concern. [1]

When it does occur, it typically takes years to develop. The average time between receiving implants and a diagnosis is about 7 to 10 years, and most patients are diagnosed in their mid-50s. [4] It most often appears as a slow-growing, localized disease, which is one reason the prognosis is generally very favorable when it is found early. [5][6]

What the outlook looks like

Most people diagnosed with BIA-ALCL have disease that is confined to the fluid-filled space around the implant. In these cases, surgical removal of the implant along with its surrounding tissue capsule is usually considered curative, without the need for chemotherapy. [5][3] In a smaller number of cases the disease spreads beyond the capsule, and additional treatment such as chemotherapy or radiation may be needed. [4][6]

Expert guidelines emphasize that plastic surgeons should be aware of the risk differences between implant types and ensure patients are properly informed. [2] Ongoing research into why BIA-ALCL develops and how to prevent it is considered a priority. [2]

What to ask your surgeon

If you have textured breast implants, consider asking your surgeon: What type of implants do I have, and what is my personal risk level? What symptoms should I watch for? How often should I be monitored? You deserve a clear, honest conversation about your individual situation based on the most current guidelines. [2][1]

Was this answer helpful?

Sources (peer-reviewed)

3.Breast implant-associated anaplastic large cell lymphoma.Cohort/SeriesTidsskr Nor Laegeforen · 2024 · PubMed
4.Breast Implant-associated Anaplastic Large Cell Lymphoma.Cohort/SeriesClin Lymphoma Myeloma Leuk · 2021 · PubMed
7.Breast implant-associated anaplastic large cell lymphoma, an under-recognised entity.Cohort/SeriesJ Med Imaging Radiat Oncol · 2019 · PubMed
Why this grade? Evidence comes from systematic reviews, expert consensus, and observational cohort studies rather than randomized controlled trials, and key figures such as exact incidence remain uncertain across the literature. · How we score evidence
← Ask another question